Delray Beach, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) — The global CAR T-cell Therapy market, valued at US$3.7 billion in 2023, stood at US$5.5 billion in 2024 and is projected to advance at a resilient CAGR of 39.6% from 2024 to 2029, culminating in a forecasted valuation of US$29.0 billion by the end of the period. This rapid acceleration underscores the convergence of critical factors: escalating cancer prevalence, robust funding pipelines, and significant technological advances in cell therapy.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47772841
Transforming Cancer Care: What Is Driving This Growth?
Cancer continues to represent one of the most pressing healthcare challenges worldwide. According to the World Health Organization, nearly 20 million new cancer cases and 9.7 million related deaths were reported in 2022, with projections estimating a 77% surge in cases by 2050. In this context, CAR T-cell therapy is emerging as a breakthrough solution, particularly in treating hematologic malignancies such as Diffuse Large B-Cell Lymphoma (DLBCL), which accounts for approximately 22% of B-cell non-Hodgkin lymphoma cases in the United States alone.
Why Now? Market Catalysts and Restraints
The rising cancer incidence and advances in genetic engineering technologies are propelling adoption of CAR T-cell therapies globally. However, accessibility remains a critical challenge. With treatment costs often surpassing USD 350,000 per patient, driven by complex manufacturing processes, affordability and scalability continue to restrict widespread adoption. At the same time, expansion into solid tumors represents an untapped opportunity for the next wave of therapeutic breakthroughs, unlocking broader applications and market potential.
Where Are the Opportunities Emerging?
Asia Pacific is forecasted to deliver the highest CAGR between 2024 and 2029, fueled by increasing healthcare investments, growing cancer incidence, and supportive regulatory frameworks. While North America remains the largest market today—thanks to early …